Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Rectal Neoplasms 4Stomach Neoplasms 3Gastrointestinal Neoplasms 3Rectal Neuroendocrine Tumors 2Esophageal Squamous Cell Carcinoma 2Colorectal Neoplasms 2Colonic Neoplasms 2Small Size Gastrointestinal Stromal Tumors 1Precancerous Conditions 1Hemorrhage 1Esophageal Neoplasms 1Duodenal Neoplasms 1Colorectal Neoplasms, Hereditary Nonpolyposis 1Colonic Polyps 1Clinical Stage III Gastric Cancer AJCC v8 1Benign Colon Tumors 1Barrett Esophagus 1Adenocarcinoma Of Esophagus 1

Interventions

berzosertib 1Magnetic Resonance Spectroscopy 1Irinotecan 1Endoscopy 1Endoscopic Mucosal Resection 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Clinical Stage III Gastric Cancer AJCC v8 × Endoscopic Mucosal Resection × 1 year × Clear all
NCT03641313 2026-04-13

Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
17 enrolled 14 charts
Gastrointestinal

Clinical Stage III Gastric Cancer AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡